Letter to the EditorPersistence of NS5B-S282T, a sofosbuvir resistance-associated substitution, in a HIV/HCV-coinfected MSM with risk of onward transmission
Section snippets
Financial support
A.N. was financially supported by the “Aidsfonds” Netherlands (grant 2013.037). The funding source had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
Conflict of interest
Marc van der Valk: through his institution has received independent scientific grant support from Gilead Sciences, Janssen Pharmaceuticals Inc, Merck & Co and ViiV Healthcare, has served on scientific advisory boards for Abbvie, BMS, Gilead Sciences, MSD and ViiV Healthcare, and has received speakers fees from Gilead Sciences. Janke Schinkel: through her institution has received independent scientific grant support from Abbvie, Gilead and MSD and Roche diagnostics, served on consultancy board
Authors’ contributions
A.N. drafted the manuscript. J.M. and M.V. are physicians treating the patient in this case report. R.M., S.R. and J.S. were responsible for laboratory analysis, and together with M.P., they also contributed to the intellectual content of the manuscript. All authors critically revised the manuscript.
References (13)
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
J Hepatol
(2016)- et al.
Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir
J Hepatol
(2017) - et al.
Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review
Ann Intern Med
(2017) - et al.
Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus
Antimicrob Agents Chemother
(2012) - et al.
In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6
Antivir Ther
(2017) - et al.
Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir
Hepatology
(2015)
Cited by (10)
Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges
2019, GastroenterologyCitation Excerpt :For example, the long-term persistence of a highly fit strain of HCV, with substitutions associated with resistance to sofosbuvir and that is difficult to treat, was recently described in a population of men who have sex with men and are coinfected with HIV and HCV. This observation raises concerns of an international spread of difficult-to-treat virus variants.56 In most patients for whom DAA therapy fails, strains of HCV emerge with variants that mediate resistance to the drug the patient received.
Viral resistance in HCV infection
2018, Current Opinion in VirologyCitation Excerpt :The presence of S282T RAS affects viral fitness and this mutation was reported to decline within 12 weeks post-treatment [54]. However, recently the persistence of this RAS was described after 21 weeks upon a failure of a sofosbuvir-based regimen in a GT4 HIV/HCV-coinfected patient [55]. Furthermore, the L159F RAS (sometimes in combination with L320F or C316N) and V321A were associated with virological failure to sofosbuvir in both clinical-trials and real world studies, particularly in GT1b and GT3 [23••,36••,56,57].
Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance
2020, Hepatology Communications